Attached files

file filename
8-K - FORM 8-K - PETMED EXPRESS INCpets20190122_8k.htm

Exhibit 99.1

 

PETMED EXPRESS D/B/A 1-800-PETMEDS ANNOUNCES ITS THIRD QUARTER FINANCIAL RESULTS AND DECLARES ITS $0.27 PER SHARE DIVIDEND

 

Delray Beach, Florida, January 22, 2019 - PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter ended December 31, 2018. Net sales were $60.1 million for both the quarters ended December 31, 2018 and 2017. Reorder sales for the quarter ended December 31, 2018 were $53.3 million, compared to $50.9 million for the quarter ended December 31, 2017, an increase of 4.6%. Net sales for the nine months ended December 31, 2018 were $218.9 million, compared to $206.5 million for the nine months ended December 31, 2017, an increase of 6.0%. Reorder sales for the nine months ended December 31, 2018 were $185.9 million, compared to $170.5 million for the nine months ended December 31, 2017, an increase of 9.0%. Net income for the quarter ended December 31, 2018 was $7.8 million, or $0.38 diluted per share, compared to net income of $9.1 million, or $0.44 diluted per share, for the quarter ended December 31, 2017, a 14% decrease to net income. Net income for the nine months ended December 31, 2018 was $31.1 million, or $1.52 diluted per share, compared to net income of $27.1 million, or $1.33 diluted per share, for the nine months ended December 31, 2017, a 15% increase to net income. Average order size decreased to $84 for the quarter ended December 31, 2018, compared to $86 for the same quarter in the prior year. For the nine months ended December 31, 2018, online sales increased 7.0% to $185.3 million from $173.2 million for the same period the prior year, and were approximately 85% of all sales.

 

Menderes Akdag, CEO and President, commented: “The market was much more competitive during the quarter, and as a result we gave additional discounts to our customers to stimulate sales, which had a negative effect on our gross margins. We will continue to be aggressive with pricing and promotions, and increase advertising to address this more competitive online market.” 

 

The Board of Directors declared a quarterly dividend of $0.27 per share on the Company’s common stock. The dividend will be payable on February 15, 2019, to shareholders of record at the close of business on February 4, 2019. The Company intends to continue to pay regular quarterly dividends; however the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance.

 

This morning at 8:30 A.M. Eastern Time, Mr. Akdag will host a conference call to review the quarter’s financial results. To access the call, which is open to the public, please dial (888) 455-1758 (toll free) or (203) 827-7025. Callers will be required to supply PETMEDS as the passcode. For those unable to participate in the live event, the call will be available for replay from 10:00 A.M. on January 22, 2019 until February 5, 2019 at 11:59 P.M. To access the replay, call (866) 457-5505 (toll free) or (203) 369-1279 and enter passcode 5500.

 

Founded in 1996, PetMed Express is America’s Largest Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs and cats at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com.

 

This press release may contain “forward-looking” statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such “forward-looking” statements are set forth in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2018. The Company’s future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K.

 

For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 561-526-4444.

###

 

Exhibit 99.1 Page 1 of 4

 

 

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except for per share data)

 

   

December 31,

   

March 31,

 
   

2018

   

2018

 

 

 

(Unaudited)

         
ASSETS              
                 

Current assets:

               

Cash and cash equivalents

  $ 93,166     $ 77,936  

Accounts receivable, less allowance for doubtful accounts of $19 and $35, respectively

    1,269       2,292  

Inventories - finished goods

    32,247       23,337  

Prepaid expenses and other current assets

    1,266       882  

Prepaid income taxes

    525       788  

Total current assets

    128,473       105,235  
                 

Noncurrent assets:

               

Property and equipment, net

    27,584       28,741  

Intangible assets

    860       860  

Total noncurrent assets

    28,444       29,601  
                 

Total assets

  $ 156,917     $ 134,836  
                 

LIABILITIES AND SHAREHOLDERS' EQUITY

               
                 

Current liabilities:

               

Accounts payable

  $ 20,283     $ 15,274  

Accrued expenses and other current liabilities

    2,769       2,835  

Total current liabilities

    23,052       18,109  
                 

Deferred tax liabilities

    1,007       996  
                 

Total liabilities

    24,059       19,105  
                 

Commitments and contingencies

               
                 

Shareholders' equity:

               

Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share

    9       9  

Common stock, $.001 par value, 40,000 shares authorized; 20,674 and 20,601 shares issued and outstanding, respectively

    21       21  

Additional paid-in capital

    11,693       9,381  

Retained earnings

    121,135       106,320  
                 

Total shareholders' equity

    132,858       115,731  
                 

Total liabilities and shareholders' equity

  $ 156,917     $ 134,836  

 

 

Exhibit 99.1 Page 2 of 4

 

 

 

 PETMED EXPRESS, INC. AND SUBSIDIARIES 

 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 

 (In thousands, except for per share amounts) (Unaudited) 

 

   

Three Months Ended

   

Nine Months Ended

 
   

December 31,

   

December 31,

 
   

2018

   

2017

   

2018

   

2017

 
                                 

Sales

  $ 60,068     $ 60,110     $ 218,854     $ 206,478  

Cost of sales

    40,687       38,166       144,264       133,590  
                                 

Gross profit

    19,381       21,944       74,590       72,888  
                                 

Operating expenses:

                               

General and administrative

    5,793       5,818       18,927       18,222  

Advertising

    3,619       4,126       15,626       14,944  

Depreciation

    556       532       1,664       1,590  

Total operating expenses

    9,968       10,476       36,217       34,756  
                                 

Income from operations

    9,413       11,468       38,373       38,132  
                                 

Other income:

                               

Interest income, net

    508       191       1,315       417  

Other, net

    255       265       827       755  

Total other income

    763       456       2,142       1,172  
                                 

Income before provision for income taxes

    10,176       11,924       40,515       39,304  
                                 

Provision for income taxes

    2,389       2,860       9,394       12,204  
                                 

Net income

  $ 7,787     $ 9,064     $ 31,121     $ 27,100  
                                 

Comprehensive income

  $ 7,787     $ 9,064     $ 31,121     $ 27,100  
                                 

Net income per common share:

                               

Basic

  $ 0.38     $ 0.45     $ 1.52     $ 1.33  

Diluted

  $ 0.38     $ 0.44     $ 1.52     $ 1.33  
                                 

Weighted average number of common shares outstanding:

                         

Basic

    20,483       20,368       20,452       20,337  

Diluted

    20,493       20,425       20,487       20,437  
                                 

Cash dividends declared per common share

  $ 0.27     $ 0.20     $ 0.79     $ 0.60  

 

 

Exhibit 99.1 Page 3 of 4

 

 

 

PETMED EXPRESS, INC. AND SUBSIDIARIES

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(In thousands) (Unaudited)

 

 

   

Nine Months Ended

 
   

December 31,

 
   

2018

   

2017

 

Cash flows from operating activities:

               

Net income

  $ 31,121     $ 27,100  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Depreciation

    1,664       1,590  

Share based compensation

    2,312       1,858  

Deferred income taxes

    11       (412 )

Bad debt expense

    49       72  

(Increase) decrease in operating assets and increase (decrease) in liabilities:

               

Accounts receivable

    974       21  

Inventories - finished goods

    (8,910 )     (1,679 )

Prepaid income taxes

    263       -  

Prepaid expenses and other current assets

    (384 )     45  

Accounts payable

    5,009       (2,795 )

Income taxes payable

    -       8,815  

Accrued expenses and other current liabilities

    (84 )     530  

Net cash provided by operating activities

    32,025       35,145  
                 

Cash flows from investing activities:

               

Purchases of property and equipment

    (507 )     (564 )

Net cash used in investing activities

    (507 )     (564 )
                 

Cash flows from financing activities:

               

Dividends paid

    (16,288 )     (12,314 )

Net cash used in financing activities

    (16,288 )     (12,314 )
                 

Net increase in cash and cash equivalents

    15,230       22,267  

Cash and cash equivalents, at beginning of period

    77,936       58,730  
                 

Cash and cash equivalents, at end of period

  $ 93,166     $ 80,997  
                 

Supplemental disclosure of cash flow information:

               
                 

Cash paid for income taxes

  $ 9,120     $ 3,801  
                 

Dividends payable in accrued expenses

  $ 258     $ 246  

 

 

Exhibit 99.1 Page 4 of 4